The Vernal keratoconjunctivitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vernal keratoconjunctivitis: An Overview
Vernal Keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. It is an IgE‐ and T cell‐mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and mixed form.
The sign and symptoms usually begin before 10 years of age and may include hard, cobblestone‐like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; and involuntary blinking or spasms of the eyelid (blepharospasm).
Vernal Keratoconjunctivitis usually subsides at the onset of puberty, and treatment is both Preventive and Therapeutic. Management of vernal Keratoconjunctivitis focuses on preventing allergic attacks as well as relieving the signs and severity of the condition.
Vernal keratoconjunctivitis Market Key Facts
The study conducted by Bremond‐Gignac D et al. “the prevalence of Vernal Keratoconjunctivitis (VKC) in Western Europe ranged from 1.16 to 10.55 and specifically in Italy and France, the prevalence is 2.4 to 27.8 and 0.7 to 3.3, respectively.
According to the study conducted by Leonardi A et al., the majority of VKC patients were male (76%), with a male: female ratio of 3.3:1 in Italy.
Vernal Keratoconjunctivitis may represent 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America.
Vernal keratoconjunctivitis market size is expected to increase during the forecast period owing to the extensive research and development activities of pharmaceutical companies for developing the Vernal keratoconjunctivitis therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Vernal keratoconjunctivitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Vernal keratoconjunctivitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market
Vernal keratoconjunctivitis Epidemiology
The epidemiology section covers insights about the historical and current Vernal keratoconjunctivitis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Total Prevalent Cases
Gender-Specific Prevalent Cases
Severity specific Prevalent Cases
Diagnosed and Treatable Cases
Vernal keratoconjunctivitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal keratoconjunctivitis market or expected to get launched in the market during the study period. The analysis covers Vernal keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Vernal keratoconjunctivitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Vernal keratoconjunctivitis Therapeutics Analysis
Currently, the Vernal keratoconjunctivitis market is facing many limitations to current management strategies includes, including the lack of well‐defined management guidelines and the choice of medications that may vary greatly for the same severity of disease from physician to physician.
To tackle the unmet need of the market which includes side effects from current medications and to avoid the overuse of steroids, some of the key companies are actively involved in the therapeutics development for VKC. In addition, if this drug is approved in upcoming years, then it will cover a decent market share.
Some of the key companies in the Vernal keratoconjunctivitis Market:
And many others.
Vernal keratoconjunctivitis Therapies covered in the report include:
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Vernal keratoconjunctivitis Competitive Intelligence Analysis
4. Vernal keratoconjunctivitis Market Overview at a Glance
5. Vernal keratoconjunctivitis Disease Background and Overview
6. Vernal keratoconjunctivitis Patient Journey
7. Vernal keratoconjunctivitis Epidemiology and Patient Population
8. Vernal keratoconjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Vernal keratoconjunctivitis Unmet Needs
10. Key Endpoints of Vernal keratoconjunctivitis Treatment
11. Vernal keratoconjunctivitis Marketed Products
12. Vernal keratoconjunctivitis Emerging Therapies
13. Vernal keratoconjunctivitis Seven Major Market Analysis
14. Attribute Analysis
15. Vernal keratoconjunctivitis Market Outlook (7 major markets)
16. Vernal keratoconjunctivitis Access and Reimbursement Overview
17. KOL Views on the Vernal keratoconjunctivitis Market.
18. Vernal keratoconjunctivitis Market Drivers
19. Vernal keratoconjunctivitis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market
Other Latest Reports By DelveInsight
As per DelveInsight, Follicular Lymphoma Market is expected to grow immensely in the coming years owing to the active participation of the key companies such as Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, BeiGene, and others.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States